FDA Publishes Notice of Patent Infringement Complaint Filed Against Biosimilar Applicant

Summary

The FDA has published a notice that a patent infringement action was filed against an applicant for a proposed biosimilar product, in connection with the applicant's biologics license application (BLA), as required under the Public Health Service Act (PHS Act). The applicant must notify FDA within 30 days after being served with the complaint.